Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
CERT
vs
S&P 500
CERT
S&P 500
Over the past 12 months, CERT has underperformed S&P 500, delivering a return of -30% compared to S&P 500's +15% growth.
Stocks Performance
CERT vs S&P 500
Performance Gap
CERT vs S&P 500
Performance By Year
CERT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Certara Inc
Glance View
Certara helps drug makers use software and scientific consulting to design and test medicines before and during clinical development. Its main products are biosimulation software tools, data and modeling platforms, and expert services that help customers predict how a drug will behave in the body and choose better trial designs. Its customers are pharmaceutical companies, biotech firms, and some regulators and academic groups that work on drug development. Certara makes money by selling software licenses and subscriptions, plus consulting and project work for specific development programs. The software usually sits inside a drug company’s research workflow, while the services help teams apply the models to real drug candidates. What makes Certara different is that it is not trying to sell the drug itself or run the trials end to end. It sells tools and expertise that help make drug development faster, more informed, and less wasteful. That gives it a role as a technical partner in the life sciences value chain, especially where companies need to understand dose, safety, and trial design before spending heavily on large studies.